Noile-Immune Biotech Inc
TSE:4893
Noile-Immune Biotech Inc
Free Cash Flow
Noile-Immune Biotech Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
N
|
Noile-Immune Biotech Inc
TSE:4893
|
Free Cash Flow
-ÂĄ873.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
TSE:2160
|
Free Cash Flow
-ÂĄ1.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
||
PeptiDream Inc
TSE:4587
|
Free Cash Flow
ÂĄ25.1B
|
CAGR 3-Years
69%
|
CAGR 5-Years
48%
|
CAGR 10-Years
80%
|
||
Takara Bio Inc
TSE:4974
|
Free Cash Flow
ÂĄ3.2B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Pharma Foods International Co Ltd
TSE:2929
|
Free Cash Flow
ÂĄ4.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
C
|
Cuorips Inc
TSE:4894
|
Free Cash Flow
-ÂĄ487m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Noile-Immune Biotech Inc
Glance View
Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
See Also
What is Noile-Immune Biotech Inc's Free Cash Flow?
Free Cash Flow
-873.1m
JPY
Based on the financial report for Dec 31, 2023, Noile-Immune Biotech Inc's Free Cash Flow amounts to -873.1m JPY.
What is Noile-Immune Biotech Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-43%
Over the last year, the Free Cash Flow growth was -715%. The average annual Free Cash Flow growth rates for Noile-Immune Biotech Inc have been -43% over the past three years .